Recent Updates
Recently added Catalysts

FP/SAL 250/

Phase 3

Asthma | Small molecule | Respiratory |GSK plc|Last Updated: Nov 25, 2016

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials2
Total Enrollment1,053
FDA Designations
No designations recorded
Clinical Trials (2)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00920959Advair Pediatric Once-DailyPHASE3 COMPLETED 908Nov 1, 2001Jan 1, 2004Sep 15, 2016149 United States, Argentina +3
NCT01248975Safety and Efficacy Study Adding GSK2190915 to Mid-dose Inhaled Corticosteroid/Long Acting Beta Agonist Combination Treatment for AsthmaPHASE2 COMPLETED 145Dec 1, 2010Oct 1, 2011Nov 25, 201619 Bulgaria, Poland +1
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Change from baseline at endpoint in daily PM PEF
12 weeks
Trough (AM pre-dose and pre-rescue bronchodilator) FEV1
at the end of the 6 week treatment period.
Secondary Endpoints
Various pulmonary function endpoints
12 weeks
• Daily trough (AM pre-dose and pre-rescue bronchodilator) AM PEF
averaged over the last 3 weeks of the 6 week treatment period.
• Daily PM PEF
averaged over the last 3 weeks of the 6 week treatment period.
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Fluticasone propionate/salmeterol combinationEXPERIMENTALstudy drug
Fluticasone propionateEXPERIMENTALstudy drug
PlaceboEXPERIMENTALplacebo
FP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM)EXPERIMENTALFP/SAL 250/50mcg BID plus GSK2190915 300mg QD (AM)
FP/SAL 250/50mcg BID plus montelukast 10mg QD (PM)ACTIVE_COMPARATORFP/SAL 250/50mcg BID plus montelukast 10mg QD (PM)
FP/SAL 250/50mcg BID plus placebo BIDPLACEBO_COMPARATORP/SAL 250/50mcg BID plus placebo BID
Interventions
NameTypeDescription
FP 100mcgDRUGOnce-daily dosing
FSC 100/50mcgDRUGOnce-daily dosing
PlaceboDRUGOnce-daily dosing
FP/SAL 250/50mcg BIDDRUGFP/SAL 250/50mcg BID
GSK2190915 200mg QD (AM)DRUGGSK2190915 200mg QD (AM)
GSK2190915 100mg QD (AM)DRUGGSK2190915 100mg QD (AM)
Montelukast 10mg QD (PM)DRUGMontelukast 10mg QD (PM)
Placebo tablets (2) (AM)DRUGPlacebo tablets (2) (AM)
Placebo capsule (PM)DRUGPlacebo capsule (PM)
Unlock Study Design Details
Eligibility Criteria
Age Range4 Years — 11 Years
SexALL
Healthy VolunteersNo
Study Sites149

Inclusion Criteria: * Out-patients * Asthma diagnosis * Reversibility * Short-acting beta-agonist or asthma controlled medication use Exclusion Criteria: * Life-threatening asthma * Specified asthma medications * Chickenpox * Drug allergy * Respiratory infections * Tobacco use * Clinical laborato...

Countries:United StatesArgentinaChilePeruPuerto RicoBulgariaPolandUkraine
Unlock Eligibility Criteria